Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (112)
  • Open Access

    REVIEW

    Biological characteristics and clinical management of uveal and conjunctival melanoma

    SNJEŽANA KAŠTELAN1,2, ANA DIDOVIĆ PAVIČIĆ3, DARIA PAŠALIĆ4, TAMARA NIKUŠEVA-MARTIĆ5, SAMIR ČANOVIĆ3,7, PETRA KOVAČEVIĆ1,6,*, SUZANA KONJEVODA3,7

    Oncology Research, Vol.32, No.8, pp. 1265-1285, 2024, DOI:10.32604/or.2024.048437

    Abstract Uveal and conjunctival melanomas are relatively rare tumors; nonetheless, they pose a significant risk of mortality for a large number of affected individuals. The pathogenesis of melanoma at different sites is very similar, however, the prognosis for patients with ocular melanoma remains unfavourable, primarily due to its distinctive genetic profile and tumor microenvironment. Regardless of considerable advances in understanding the genetic characteristics and biological behaviour, the treatment of uveal and conjunctival melanoma remains a formidable challenge. To enhance the prospect of success, collaborative efforts involving medical professionals and researchers in the fields of ocular biology… More > Graphic Abstract

    Biological characteristics and clinical management of uveal and conjunctival melanoma

  • Open Access

    ARTICLE

    An Immune-Inspired Approach with Interval Allocation in Solving Multimodal Multi-Objective Optimization Problems with Local Pareto Sets

    Weiwei Zhang1, Jiaqiang Li1, Chao Wang2, Meng Li3, Zhi Rao4,*

    CMC-Computers, Materials & Continua, Vol.79, No.3, pp. 4237-4257, 2024, DOI:10.32604/cmc.2024.050430

    Abstract In practical engineering, multi-objective optimization often encounters situations where multiple Pareto sets (PS) in the decision space correspond to the same Pareto front (PF) in the objective space, known as Multi-Modal Multi-Objective Optimization Problems (MMOP). Locating multiple equivalent global PSs poses a significant challenge in real-world applications, especially considering the existence of local PSs. Effectively identifying and locating both global and local PSs is a major challenge. To tackle this issue, we introduce an immune-inspired reproduction strategy designed to produce more offspring in less crowded, promising regions and regulate the number of offspring in areas… More >

  • Open Access

    ARTICLE

    Fibroblast Activation Protein-α-Positive Fibroblasts Promote Gastric Cancer Progression and Resistance to Immune Checkpoint Blockade

    Xuyang Wen*, Xiaoping He, Feng Jiao, Chunhui Wang§, Yang Sun, Xuequn Ren, Qianwen Li*

    Oncology Research, Vol.25, No.4, pp. 629-640, 2017, DOI:10.3727/096504016X14768383625385

    Abstract Gastric cancer (GC) is one of the main causes of cancer death. The tumor microenvironment has a profound effect on inducing tumor growth, metastasis, and immunosuppression. Fibroblast activation protein-a (FAP) is a protein that is usually expressed in fibroblasts, such as cancer-associated fibroblasts, which are major components of the tumor microenvironment. However, the role of FAP in GC progression and treatment is still unknown. In this study, we explored these problems based on GC patient samples and experimental models. We found that high FAP expression was an independent prognosticator of poor survival in GC patients. More >

  • Open Access

    ARTICLE

    CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model

    Xiaolin Miao*1, Yiqi Chen*1, Ke Hao†1, Meiqin Zheng, Bingyu Chen, Kaiqiang Li, Ying Wang, Wei Zhang§, Yu Zhang§, Xiaozhou Mou§, Shanshan Jiang, Zhen Wang‡§

    Oncology Research, Vol.26, No.2, pp. 173-182, 2018, DOI:10.3727/096504017X14841698396865

    Abstract Glioblastoma is a lethal disease featuring a high proliferation of tumor cells, excessive angiogenesis, and heavy drug resistance. The overall survival of glioblastoma patients has been dismal, even with an intensive standard of care. Recent advances in immune checkpoint blockades are changing the treatment of cancers. However, the efficacy of immune checkpoint blockades in glioblastoma is still unclear. Here we investigated the roles of CD103+ cells in regulating the effect of immune checkpoint blockades in glioblastoma mouse models. Our findings indicated that the murine glioblastoma model was not sensitive to immune checkpoint blockades. Flt3L, a growth More >

  • Open Access

    ARTICLE

    PHLDA2 reshapes the immune microenvironment and induces drug resistance in hepatocellular carcinoma

    KUN FENG1,#, HAO PENG2,#, QINGPENG LV1, YEWEI ZHANG1,*

    Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078

    Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

  • Open Access

    ARTICLE

    CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

    KAIWEN TIAN#, HANZHONG CHEN#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG*, JIUMIN LIU*

    BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737

    Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

    CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

  • Open Access

    ARTICLE

    Bioinformatics comprehensive analysis confirmed the potential involvement of SLC22A1 in lower-grade glioma progression and prognosis

    JING HUI1,2, NANA SUN3, YONG LIU4, CHUNBO YU1,2, YONG KE4, YONG CAO4, ANXIAO YU4, QINGHONG KONG1,2,*, YUN LIU1,2,4,*

    BIOCELL, Vol.48, No.5, pp. 803-815, 2024, DOI:10.32604/biocell.2024.047122

    Abstract Background: Although it has been established that the human Solute Carrier Family 22 (SLC22) functions as a cationic transporter, influencing cellular biological metabolism by modulating the uptake of various cations, its impact on cancer prognosis remains unclear. Methods: We conducted a comprehensive analysis utilizing data from The Cancer Genome Atlas (TCGA) and other databases to assess the prognostic value and functional implications across various tumors. Silence of SLC22A1 RNA in glioma U251 cells was performed to access the impact of SLC22A1 on lower-grade glioma (LGG) progression. Results: Our findings demonstrated a significant correlation between SLC22A1 expression… More >

  • Open Access

    ARTICLE

    Multi-cohort comprehensive analysis unveiling the clinical value and therapeutic effect of GNAL in glioma

    ZHEN LIU1,#, LIANGWANG YANG2,#, ZHENGXING XIE1, HUI YU3, TIANYI GU3, DAOMING SHI4, NING CAI1,*, SHENGHUA ZHUO2,*

    Oncology Research, Vol.32, No.5, pp. 965-981, 2024, DOI:10.32604/or.2024.045769

    Abstract Clinical data indicates that glioma patients have poor treatment outcomes and clinical prognosis. The role of olfactory signaling pathway-related genes (OSPRGs) in glioma has not been fully elucidated. In this study, we aimed to investigate the role and relationship between OSPRGs and glioma. Univariate and multivariate Cox regression analyses were performed to assess the relationship between OSPRGs and the overall survival of glioma based on public cohorts, and the target gene (G Protein Subunit Alpha L, GNAL) was screened. The association of GNAL expression with clinicopathological characteristics, gene mutation landscape, tumor immune microenvironment (TIME), deoxyribonucleic acid… More >

  • Open Access

    ARTICLE

    IQGAP3 promotes the progression of glioma as an immune and prognostic marker

    XIAOFENG GAO1,2,3,4, JUANJUAN GE3, XUZHENG GAO1,3, NA MEI1,3, YANTING SU3, SHIGANG SHAN3, WENBIN QIAN3, JIANGHENG GUAN5, ZHENWANG ZHANG1,3,*, LONG WANG2,3,4,*

    Oncology Research, Vol.32, No.4, pp. 659-678, 2024, DOI:10.32604/or.2023.046712

    Abstract Background: IQGAP3 plays a crucial role in regulating cell proliferation, division, and cytoskeletal organization. Abnormal expression of IQGAP3 has been linked to various tumors, but its function in glioma is not well understood. Methods: Various methods, including genetic differential analysis, single-cell analysis, ROC curve analysis, Cox regression, Kaplan-Meier analysis, and enrichment analysis, were employed to analyze the expression patterns, diagnostic potential, prognostic implications, and biological processes involving IQGAP3 in normal and tumor tissues. The impact of IQGAP3 on immune infiltration and the immune microenvironment in gliomas was evaluated using immunofluorescence. Additionally, the cBioPortal database was used… More > Graphic Abstract

    IQGAP3 promotes the progression of glioma as an immune and prognostic marker

  • Open Access

    REVIEW

    The heterogeneity of tumor-associated macrophages and strategies to target it

    HAO LV1, BO ZHU1,2, DEGAO CHEN1,2,*

    BIOCELL, Vol.48, No.3, pp. 363-378, 2024, DOI:10.32604/biocell.2023.046367

    Abstract Tumor-associated macrophages (TAMs) are emerging as targets for tumor therapy because of their primary role in promoting tumor progression. Several studies have been conducted to target TAMs by reducing their infiltration, depleting their numbers, and reversing their phenotypes to suppress tumor progression, leading to the development of drugs in preclinical and clinical trials. However, the heterogeneous characteristics of TAMs, including their ontogenetic and functional heterogeneity, limit their targeting. Therefore, in-depth exploration of the heterogeneity of TAMs, combined with immune checkpoint therapy or other therapeutic modalities could improve the efficiency of tumor treatment. This review focuses More >

Displaying 1-10 on page 1 of 112. Per Page